Mountain View Pharmaceuticals, Inc. Announces Receipt of a U.S. Patent on Next-Generation PEGylation Technology (PharmaPEG)
3/14/2012 7:09:40 AM
MENLO PARK, Calif.--(BUSINESS WIRE)--Mountain View Pharmaceuticals, Inc. (“MVP”) announced today its receipt of U.S. Patent No. 8,129,330 B2 titled “Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof.
comments powered by